Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 190.37 USD -2.02% Market Closed
Market Cap: 11.5B USD

Wall Street
Price Targets

ASND Price Targets Summary
Ascendis Pharma A/S

Wall Street analysts forecast ASND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ASND is 254.17 USD with a low forecast of 205.03 USD and a high forecast of 322.35 USD.

Lowest
Price Target
205.03 USD
8% Upside
Average
Price Target
254.17 USD
34% Upside
Highest
Price Target
322.35 USD
69% Upside
Ascendis Pharma A/S Competitors:
Price Targets
ARCT
Arcturus Therapeutics Holdings Inc
255% Upside
XOMA
XOMA Corp
95% Upside
DVAX
Dynavax Technologies Corp
136% Upside
GLUE
Monte Rosa Therapeutics Inc
262% Upside
688177
Bio-Thera Solutions Ltd
13% Upside
LTRN
Lantern Pharma Inc.
346% Upside
2480
Beijing Luzhu Biotechnology Co Ltd
26% Upside
BRNS
Barinthus Biotherapeutics PLC
284% Upside

Revenue
Forecast

Revenue Estimate
Ascendis Pharma A/S

For the last 11 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 30%. The projected CAGR for the next 3 years is 72%.

30%
Past Growth
72%
Estimated Growth
Estimates Accuracy
4%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Ascendis Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

Net Income Estimate
Ascendis Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-19%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ASND's stock price target?
Price Target
254.17 USD

According to Wall Street analysts, the average 1-year price target for ASND is 254.17 USD with a low forecast of 205.03 USD and a high forecast of 322.35 USD.

What is Ascendis Pharma A/S's Revenue forecast?
Projected CAGR
72%

For the last 11 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 30%. The projected CAGR for the next 3 years is 72%.

Back to Top